Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Given Consensus Recommendation of “Buy” by Analysts

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) has been given an average recommendation of “Buy” by the six ratings firms that are presently covering the stock, Marketbeat reports. Six analysts have rated the stock with a buy rating. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $67.60.

A number of research firms have recently commented on ARCT. Canaccord Genuity Group reduced their price objective on shares of Arcturus Therapeutics from $87.00 to $86.00 and set a “buy” rating on the stock in a research note on Friday, May 10th. HC Wainwright reaffirmed a “buy” rating and set a $60.00 price target on shares of Arcturus Therapeutics in a research report on Tuesday, July 2nd. Finally, William Blair reissued an “outperform” rating on shares of Arcturus Therapeutics in a research report on Thursday, May 23rd.

Insiders Place Their Bets

In other news, COO Pad Chivukula sold 26,000 shares of the company’s stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $40.01, for a total transaction of $1,040,260.00. Following the transaction, the chief operating officer now owns 447,448 shares in the company, valued at $17,902,394.48. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 13.80% of the company’s stock.

Institutional Investors Weigh In On Arcturus Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. Russell Investments Group Ltd. bought a new stake in Arcturus Therapeutics during the 1st quarter valued at $40,000. AJOVista LLC acquired a new position in shares of Arcturus Therapeutics during the fourth quarter valued at about $65,000. Quest Partners LLC bought a new stake in shares of Arcturus Therapeutics during the fourth quarter worth about $67,000. Public Employees Retirement System of Ohio acquired a new stake in shares of Arcturus Therapeutics in the 4th quarter worth about $89,000. Finally, China Universal Asset Management Co. Ltd. raised its holdings in shares of Arcturus Therapeutics by 352.3% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 3,089 shares of the biotechnology company’s stock worth $97,000 after acquiring an additional 2,406 shares during the last quarter. Institutional investors own 94.54% of the company’s stock.

Arcturus Therapeutics Price Performance

Arcturus Therapeutics stock opened at $20.55 on Friday. The business has a 50 day moving average of $27.52 and a 200-day moving average of $31.10. Arcturus Therapeutics has a 1 year low of $17.52 and a 1 year high of $45.00. The company has a market capitalization of $553.41 million, a P/E ratio of -5.26 and a beta of 2.64.

Arcturus Therapeutics (NASDAQ:ARCT) last posted its quarterly earnings data on Wednesday, May 8th. The biotechnology company reported ($1.00) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.17) by $0.17. The business had revenue of $38.01 million during the quarter, compared to the consensus estimate of $22.12 million. Arcturus Therapeutics had a negative return on equity of 37.61% and a negative net margin of 81.59%. Equities analysts anticipate that Arcturus Therapeutics will post -4.74 EPS for the current year.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.